Analytical Data
-
Gene name
CD161
- Application
-
Alternative Names
KLRB1; KLR-B1; CLEC5B; NKR; NKR-P1; NKR-P1A; NKRP1A; HNKR-P1A; Killer Cell Lectin Like Receptor Subfamily B, Member 1; C-type lectin domain family 5 member B; Natural killer cell surface protein P1A
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q12918
-
Expression Region
Gln67~Ser225
-
Molecular Weight
24kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD161, also known as the killer cell lectin-like receptor subfamily C member 1 (KLRB1), is a type II transmembrane protein predominantly expressed on natural killer (NK) cells and some T cell subsets. Its role in modulating immune responses makes it an important focus of research, particularly in cancer immunotherapy and infectious diseases. Studies have shown that CD161 acts as an inhibitory receptor, influencing the activation and cytotoxic functions of NK cells, thereby affecting tumor surveillance and pathogen control. The understanding of CD161's signaling pathways and ligand interactions is crucial, as it may open new avenues for therapeutic interventions. Recombinant proteins of CD161 have been developed to study its biological functions, receptor-ligand dynamics, and regulatory mechanisms in immune responses. These recombinant proteins are instrumental for functional assays, structural analysis, and the development of potential CD161-targeted therapies. The increasing interest in modulating CD161 to enhance immune efficacy highlights its potential as a biomarker for immune status and a target for new immunotherapeutic strategies, providing insights into the complex interplay between innate and adaptive immunity.
